Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.2Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: -5.41%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
The earnings call presents a mixed outlook. While there were significant achievements in clinical trials, licensing agreements, and financial position improvements, these were balanced by increased net losses, operating expenses, and market challenges in the US heart failure sector.Company Guidance
In the recent Lexicon Pharmaceuticals conference call discussing their fourth quarter and full year 2024 financial results, the company provided several key metrics and updates on their clinical programs. Lexicon reported a net loss of $33.8 million for the fourth quarter, compared to a $49.8 million loss in the same period in 2023. Revenue for the fourth quarter was $26.6 million, with $31.1 million for the full year. They ended 2024 with $238 million in cash and investments, up from $170 million at the end of 2023. The company outlined plans for their clinical trials, including the PROGRESS Phase 2b study of pillabapentin, which showed a 1.74-point reduction in ADPS at the 10-milligram dose. Additionally, Lexicon is advancing their LX9851 IND enabling studies and anticipates filing in 2025. For 2025, they expect total operating expenses between $135 million and $145 million, with R&D expenses projected at $100 million to $105 million.Successful Phase 2b PROGRESS Study
The PROGRESS Phase 2b study of pillabapentin for diabetic peripheral neuropathic pain (DPNP) showed a clear separation in ADPS from baseline, with the 10-milligram dose showing meaningful improvement compared to placebo and improved tolerability.
Significant Licensing Agreement
Lexicon entered into a significant licensing agreement with Beatrice for sotagliflozin outside of the US and Europe, contributing a $25 million upfront payment.
Strong Financial Position
Ended 2024 with $238 million in cash, cash equivalents, and short-term investments, an increase from $170 million at the end of 2023.
Potential of Sotagliflozin
Research highlighted sotagliflozin's effects in reducing major adverse cardiovascular events, myocardial infarction, and stroke, showing promise as a differentiated SGLT1 and 2 inhibitor.
---
LXRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LXRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $0.37 | $0.39 | +5.41% |
| Nov 12, 2024 | $1.19 | $1.09 | -8.40% |
| Aug 01, 2024 | $2.02 | $1.70 | -15.84% |
| May 02, 2024 | $1.70 | $1.74 | +2.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lexicon Pharmaceuticals (LXRX) report earnings?
Lexicon Pharmaceuticals (LXRX) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Lexicon Pharmaceuticals (LXRX) earnings time?
Lexicon Pharmaceuticals (LXRX) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LXRX EPS forecast?
LXRX EPS forecast for the fiscal quarter 2025 (Q1) is -0.09.
---